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The first European Quality Control Concerted Action study was organized to assess the ability of labora-
tories to detect Chlamydia trachomatis in a panel of urine samples by nucleic acid amplification tests (NATs).
The panel consisted of lyophilized urine samples, including three negative, two strongly positive, and five
weakly positive samples. Ninety-six laboratories in 22 countries participated with a total of 102 data sets. Of
204 strongly positive samples 199 (97.5%) were correctly reported, and of 506 weakly positive samples 466
(92.1%) were correctly reported. In 74 (72.5%) data sets correct results were reported on all samples, and 17
data sets (16.7%) showed either one false-negative or one false-positive result. In another 11 data sets, two or
more incorrect results were reported, and two data sets reported a false-positive result on one negative sample.
The Roche COBAS Amplicor test was performed in 44 (43%) data sets, the Abbott LCx assay was performed
in 31 (30%) data sets, the Roche Amplicor manual assay was performed in 9 (9%) data sets, an in-house PCR
was performed in 9 (9%) data sets, the Becton Dickinson ProbeTec ET assay was performed in 5 (4.9%) data
sets, and the GenProbe TMA assay was performed in 4 (3.9%) data sets. The results of the Roche Amplicor
manual (95.6% correct), COBAS Amplicor (97.0%), and Abbott LCx (94.8%) tests were comparable (P 0.48).
The results with the in-house PCR, BD ProbeTec ET, and GenProbe TMA tests were reported correctly in 88.6,
98, and 92.5% of the tests, respectively. Freeze-drying of clinical urine specimens proved to be a successful
method for generating standardized, stable, and easy-to-transport samples for the detection of C. trachomatis
by using NATs. Although the results, especially the specificity, for this proficiency panel were better than most
quality control studies, sensitivity problems occurred frequently, underlining the need for good laboratory
practice and reference reagents to monitor the performance of these assays.
A multiplicity of nucleic acid amplification test (NAT) pro-
cedures are now available for the diagnosis of Chlamydia tra-
chomatis infections. C. trachomatis amplification tests can be
performed on endocervical or urethral swab specimens and
urines (6). In addition to in-house PCR tests, commercial NAT
assays are available, such as Abbott LCx, Becton Dickinson
ProbeTec ET, GenProbe TMA, and Roche Amplicor (COBAS
and manual) PCRs. All tests aim to be rapid, sensitive, specific,
and easy to perform. However, previous studies have shown
that application of NATs may be unreliable because of cross-
contamination, inappropriate treatment of the clinical samples
leading to the loss of target DNA, or the presence of inhibitors
in the sample (1, 3, 8, 11).
Members of the European Union Concerted Action on
Quality Control (EU-QCCA) of Nucleic Acid Amplification in
Diagnostic Virology and members of the Study Group on Mo-
lecular Diagnostics of the European Society for Clinical Mi-
crobiology and Infectious Diseases formed a working party to
establish a quality assessment program for the evaluation of
currently used NATs for the detection of C. trachomatis. The
aim of the study was to assess the quality performance of
laboratories for detection of C. trachomatis in a panel of sam-
ples that could be tested with all existing commercial and
in-house test systems and that would resemble clinical samples.
Since commercial systems require their specific transport me-
dium for swab specimens, urine samples were chosen as the
most suitable specimen for the EU-QCCA panel. All commer-
cial systems include a protocol for testing C. trachomatis in
urine samples.
In order to avoid the high costs associated with shipment of
infectious goods on dry ice, lyophilized urine specimens were
prepared.
MATERIALS AND METHODS
Collection of urine samples. Negative urine samples were obtained by collect-
ing up to 50 ml of early morning first-catch urine samples over a period of 3
months from two healthy females (urine samples B and C) and one healthy male
volunteer (urine sample D). Urine samples from each volunteer were pooled.
The volunteers had no history of infection with C. trachomatis or N. gonorrhoeae,
and the pools were examined for these microorganisms by culture and NAT.
These tests were all negative. A mixture of urine types was formed by mixing
equal amounts of the pooled urine samples (mix A).
First-catch urine samples from patients visiting the clinics for sexually trans-
mitted diseases of the Erasmus Medical Center in Rotterdam, The Netherlands,
and of the National Institute of Public Health in Oslo, Norway, were collected
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and stored at 4°C. Samples were tested for the presence C. trachomatis DNA and
Neisseria gonorrhoeae DNA with the Roche COBAS Amplicor PCR and the
Abbott LCx tests according to the manufacturer’s procedures. C. trachomatis-
positive urine samples were diluted 101 and 102 and retested the same day.
Urine samples positive at the 102 dilution were considered strongly positive.
After estimation of the volumes, all urine samples were frozen at 70°C, with
two extra aliquots of 1 ml for further pilot testing. It appeared that some of the
urine samples from Rotterdam, but not those from Oslo, contained N. gonor-
rhoeae DNA in addition to C. trachomatis DNA.
All positive urine samples were thawed, and two different pools were prepared.
The 28 urine samples collected in Rotterdam were used to prepare a C. tracho-
matis-positive–N. gonorrhoeae-positive urine pool (pool I). The 22 urine samples
collected in Oslo were used to prepare a C. trachomatis-positive–N. gonorrhoeae-
negative urine pool (pool II). Tenfold dilutions of pools I and II were prepared
in the C. trachomatis-N. gonorrhoeae-negative urine mix, and 1.7-ml aliquots were
freeze-dried by using a Leybold-Hereaus GT 2 freeze-drier and housed in a
temperature-controlled environment (17°C).
Quality control assurance and production of the panel. The lowest dose 50%
endpoint (LD50) was defined as the lowest concentration of target that gave a
50% chance of a positive test result. The 10-fold dilutions of urine pools I and II
were tested six times by each of four different commercial test systems: Abbott
LCx, BD ProbeTec ET, COBAS Amplicor PCR, and GenProbe TMA. Three
ampoule contents were pooled to provide the 4-ml volume required by the BD
ProbeTec ET test. The LD50 value of a positive response in each test was
calculated by the method of Ka¨rber (7). The weakly positive samples in the final
panel contained 10 times the concentration of the LD50.
The final panel consisted of 10 1.7-ml portions of lyophilized urine samples: 3
negative samples, 2 strongly positive samples, and 5 weakly positive samples.
Three different urine samples from healthy volunteers were used for dilution of
the positive pool I and II to generate a heterogeneous panel (Table 1). The
samples were coded and randomized.
Quality assurance for the quality control panel was performed by four refer-
ence laboratories, and tests were performed with Abbott LCx, BD ProbeTec ET,
COBAS Amplicor PCR, and GenProbe TMA. Laboratories performing the BD
ProbeTec assay received three vials of each specimen; these had to be pooled after
restoring the volume to 1.7 ml to obtain the requested specimen volume of 4 ml.
Organization of the study. The proficiency panel was distributed from the
production laboratory in Oslo, Norway, by surface mail at ambient temperature
to the participants. The packet also included an information sheet with instruc-
tions as to how to open the vials and restore the volume to 1.7 ml. Reporting of
arrival, results, questionnaire, coding, and confidentiality was organized as de-
scribed previously (15). The Neutral Office in Manchester, United Kingdom,
received all results. Data were analyzed anonymously in Leeuwarden and Rot-
terdam, The Netherlands, by using the Statistical Package for the Social Science
(SPSS version 10). Statistical evaluation of the collected data was performed by
using the Fisher exact test; probability tests were two-tailed.
RESULTS
Validation of freeze-drying of C. trachomatis-infected urine
specimens. A set of 1-ml portions of 10-fold dilutions of a pool
of strongly positive urine samples was lyophilized, randomized,
and sent to other laboratories to test for the presence of C.
trachomatis DNA or RNA with COBAS Amplicor PCR (five
laboratories), Abbott LCx (four laboratories), GeneProbe
TMA (two laboratories), and BD ProbeTec ET (one labora-
tory); one set of samples was tested with the Vidas Probe assay
(Biomerieux, Boston, Mass.). Reproducible results were re-
ceived from duplicate series tested with the same method at
the same or at different laboratories. The sensitivity of the
COBAS Amplicor, LCx, Vidas Probe, and BD ProbeTec ET
assays were similar: dilutions 103 to 104 tested positive. The
laboratories performing the GenProbe TMA assay reported a
lower sensitivity (102 to 103); this probably resulted from
the use of a 1- ml specimen, whereas the provider prescribes
1.5-ml of urine to be tested. Samples from the same batch were
stored at room temperature and retested 5 months and 1 year
later with COBAS Amplicor and LCx. Comparable results
were obtained that confirmed that the lyophilized samples
were stable for at least 12 months.
Distribution and response. The panel was sent to 105 labo-
ratories in 22 countries. The median transport time was 3 days,
with a range of 1 to 36 days. Results were received from 96
participants (91.4%). Ninety laboratories returned one data
set, and six participants performed two tests and returned two
data sets, which yielded a total of 102 evaluable data sets.
Performance of the laboratories. In total, 304 negative sam-
ples were tested. The composition of the panel and the results
on the individual samples are presented in Table 1. Only two
laboratories reported one false-positive result; these were both
experienced laboratories examining more than 2,000 samples
per year. Of the 204 strongly positive samples, 199 (97.5%)
were reported correctly; of 506 examinations of weakly positive
samples, 466 (92.1%) were reported correctly.
In 74 (72.5%) data sets all samples were reported correctly.
In 17 (16.7%) data sets one incorrect result was reported, in 16
of these 1 weakly positive sample was reported as a false-
negative result. In six (5.9%) data sets two weakly positive
samples were reported incorrectly; one (1%) data set missed
three weakly positive samples. In three (2.9%) data sets two or
three weakly positive samples plus one or two strongly positive
samples were reported incorrectly, and one (1%) data set in-
TABLE 1. Composition of the panel and overview of correct results per sample
Sample no.
Composition of the sample
Expected result No. of samplestested
No. of correct
results (%)Background Positive urineaddedb
2 Urine B Negative 101 100 (99.0)
5 Urine C Negative 102 102 (100)
9 Urine D Negative 101 100 (99.0)
1 Mix Aa I Strongly positive 102 100 (98.0)
4 Mix A II Strongly positive 102 99 (97.1)
3 Urine B I Weakly positive 101 95 (94.1)
6 Urine C I Weakly positive 102 92 (90.2)
7 Urine C I Weakly positive 101 93 (92.1)
8 Mix A I Weakly positive 102 97 (95.1)
10 Mix A II Weakly positive 100 89 (89.0)
a Mix A is a mixture of equal volumes of urine samples B, C, and D.
b Positive urine pool I contained C. trachomatis and N. gonorrhoeae. Pool II contained C. trachomatis.
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correctly reported one weakly positive sample, one strongly
positive sample, and one negative sample.
Relation between score, type of assay, and procedures. Table
2 presents an overview of the scores classified by the type of
assay used. The BD ProbeTec ET has the highest rate (98.0%)
of correct results; however, only five participants used this new
assay. Equal percentages of correct results were reported with
the two Roche tests—Amplicor manual (95.6%) and COBAS
Amplicor (97.0%)—and with the Abbott LCx test (94.8%) (P
 0.48). The GenProbe TMA test scored lower (92.5%) be-
cause only 85% of the results of the weakly positive samples
were correctly reported. This result was in accordance with the
expected performance of the test as predicted by the random
chance calculation of the results from pilot tests and LD50
calculations (data not shown). The in-house PCR tests had the
lowest score (88.6% correct results).
Application of an internal control to monitor inhibition of
the reaction in each sample was reported by 42 data sets. Three
participants, two using COBAS-Amplicor and one using in-
house PCR, reported one or more samples with inhibition.
When these samples were tested again, the inhibition problem
was solved in the COBAS Amplicor assay but not in the in-
house PCR assay.
The majority of participants (91.7%) were laboratories that
carry out NAT for clinical diagnostics, 76 (79.2%) were hospital
or public health laboratories, and 12 (12.5%) were commercial
(private) laboratories. Five (5.2%) laboratories mentioned that
they were manufacturers of NAT assays. Three participants did
not answer this question. Commercial (private) laboratories
tended to score lower than diagnostic laboratories and manufac-
turers (92.8, 95.7, and 100%, respectively; P  0.08).
The number of NATs performed for detection of C. tracho-
matis on an annual basis varied from one laboratory perform-
ing 10 to 100 tests up to 21 laboratories examining more than
10,000 samples. More than 80% of the respondents were ex-
perienced users of NATs (1,000 tests per year). However,
there was no correlation between the number of tests per-
formed annually and the quality of the results.
Four participants performed NAT in a single laboratory
room; data sets from these labs showed a higher number of
incorrect results, i.e., 6 of 39 (15.4%) versus 41 of 945 (4.3%)
for those using more than one room (P  0.008).
DISCUSSION
This is the first international quality control study for the
detection of C. trachomatis based on molecular diagnostic
methods and lyophilized urine samples. The pilot studies and
the results from the final panel show that freeze-drying of
clinical urine samples for NATs is a successful method for
obtaining stable, standardized samples that are easy to trans-
port.
The panel was composed to resemble clinical samples, with
strongly and weakly positive urine samples from women and
men. The weakly positive samples contained approximately the
same number of C. trachomatis organisms believed to be
present in asymptomatic infected humans (R. P. Verkooyen,
unpublished data). Since more than 60% of all female C.
trachomatis infections are asymptomatic, the working party
thought it important that participants should be able to detect
these low numbers of bacteria. Also, population-based screen-
ing for C. trachomatis is expected to detect many asymptomatic
infections (2, 5, 13).
Since double infection with C. trachomatis and N. gonor-
rhoeae has been observed frequently (9, 14), we investigated
whether the tests were able to cope with samples containing
both C. trachomatis and N. gonorrhoeae. The results showed
that the presence of these dual targets did not adversely affect
test sensitivity for C. trachomatis (Table 1).
The scores described here were very good; 89.2% of data
sets scored 90% or higher. However, five (5%) data sets scored
70%. The primary purpose of the proficiency testing was to
estimate whether a laboratory is capable of providing reliable
results and not to test the performance of different commercial
assays. However, as the number of participants applying cer-
tain commercial assays was high, the results also yielded useful
information on the assays used. It showed that there was no
significant difference between the Roche PCR and the Abbott
LCx tests, although the mean score from the LCx test was 2.2%
lower. This difference was mainly due to the errors with the
weakly positive samples. Results from the pilot tests suggest
that COBAS Amplicor and LCx tests have the same chance of
correctly reporting weakly positive samples. The fact that the
results from participants in study performing the LCx assay
were slightly less successful than with the COBAS assay may be
due to inhibition of the amplification reaction sample (1, 3, 8,
11). From previous investigations we learned that the accuracy
of molecular tests with urine samples may be compromised if
urine residues remain after centrifugation; such a problem
would not be detected in the LCx system since this system lacks
an internal inhibition control. On the other hand, a weakly
positive sample may also be missed when the pellet is lost after
TABLE 2. Comparison of results and type of assay
Method No. ofdata sets
No. of samples with correct results/no. of samples tested (%)
Negative samples Strongly positive samples Weakly positive samples All samples
COBAS Amplicor 44 131/132 (99.2) 87/88 (98.9) 207/218 (95.0) 425/438 (97.0)
Abbott LCx 31 92/93 (98.9) 59/62 (95.2) 142/154 (92.2) 293/309 (94.8)
Amplicor manual 9 27/27 (100.0) 18/18 (100.0) 41/45 (91.1) 86/90 (95.6)
PCR (in house) 9 25/25 (100.0) 17/18 (94.4) 36/45 (80.0) 78/88 (88.6)
BD Probe Tec ET 5 15/15 (100.0) 10/10 (100.0) 23/24 (95.8) 48/49 (98.0)
GenProbe TMA 4 12/12 (100.0) 8/8 (100.0) 17/20 (85.0) 37/40 (92.5)
Total 102 302/304 (99.3) 199/204 (97.5) 466/506 (92.1) 967/1014 (95.4)
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centrifugation. In that case, there is no inhibition and a false-
negative test result is reported.
Previous quality control studies revealed that the number of
manually performed pretreatment steps and the difficulty of
processing samples before samples enter an automatic system
are the major causes of false-positive and false-negative results
(4, 10, 12, 17). The procedures used for the detection of C.
trachomatis in urine samples have relatively simple pretreat-
ment protocols, which may explain the differences in results
between this quality control study and the other studies. The
present study shows a very low number of false-positive results,
and only two negative samples were reported as positive in two
different data sets. These low rates were also reported in recent
quality control studies and may reflect the greater expertise of
the participating laboratories compared to several years ago
and the increasing use of commercial kits in general (15, 16).
In the present study, weakly positive samples were missed
approximately three times more frequently than the strongly
positive samples, indicating a problem in test sensitivity. The
question always arises as to whether in-house PCR amplifica-
tion is suitable for routine clinical microbiological diagnostics.
The group using in-house PCR tests had the lowest mean score
(88.6% correct results), which shows that results obtained by
in-house amplification procedures should be interpreted with
care.
For each of the commercial methods the manufacturer pre-
scribes the volume of sample to be used. Participants were
asked to calculate the sample volume equivalent used in the
amplification reaction and to report whether they adhered to
the manufacturer’s protocol. These answers were not always in
concordance; some participants calculated a different volume
than the one prescribed but answered that they used the man-
ufacturer’s protocol. In some cases, only 50% of the prescribed
volumes for reagents and sample were used. Use of a smaller
or a larger volume may compromise the sensitivity of the
method or increase the inhibition rate. Ten participants appar-
ently used lower equivalents of urine in the test than are
prescribed by the manufacturer, resulting in a significant de-
crease in sensitivity, compared to the participants who used the
prescribed sample equivalents (P  0.036). Only three partic-
ipants violated the test protocol by increasing the equivalent
sample volume used in the test. No significant difference was
observed in these cases.
Participation from different European countries was low in
comparison to the number of laboratories performing NATs
for the detection of C. trachomatis. Some laboratories may
underestimate the importance of external quality assessment
as part of quality management systems. At the time of the
present study, only 31.2% of participant laboratories were ac-
credited. We expect that the need for QC panels will increase
if in more countries accreditation becomes obligatory. The
outcome of the present study underlines the need for reference
reagents and standardized operating procedures, which would
enable experienced technicians to perform reliable quality con-
trol assessment of nucleic acid amplification methods. The first
steps are taken toward a standardized procedure for quality
control of nucleic acid amplification assays for the detection of
C. trachomatis, which should be available for every laboratory
performing NATs in routine clinical practice.
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